Provectus Biopharmaceuticals, Inc.
http://www.provectusbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Provectus Biopharmaceuticals, Inc.
All Over For Acorda After A Torrid Few Years
The embattled US biotech has gone into Chapter 11 and linked up with 'stalking horse' bidder Merz which has offered $185m to get hold of Ampyra for multiple sclerosis and Parkinson’s therapy Inbrija.
Eiger To Close After GLP-1 Antagonist Gambit Fails
The company had pivoted towards a drug with the opposite mechanism to Novo Nordisk’s Wegovy, but ran out of time and money.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Otsuka Counts The Cost Of Alzheimer’s Agitation Fail
The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
- Laser
- Other Names / Subsidiaries
-
- Provectus Biopharmaceuticals Australia Pty Ltd.
- Provectus Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice